Breast　cancer,　characterized　by　the　unchecked　proliferation　of　breast　cells,　which　usually　leads　to　invasive　behaviors　and　metastatic　spread,　is　a　pervasive　and　multifaceted　disease　and　remains　the　foremost　cause　of　death　in　women　across　the　world.　Tens　of　chemotherapeutics　have　already　been　approved　for　breast　cancer　therapy,　but　multidrug　resistance　and　severe　side　effects　have　increased　both　mortality　and　morbidity　as　a　consequence　of　treatment　failures,　creating　an　urgent　need　to　develop　novel　chemotherapeutics.　Quinazoline　hybrids　with　structural　variations　could　affect　breast　cancer　in　distinct　manners　and　have　the　potential　to　enhance　efficacy,　reduce　side　effects,　and　address　multidrug　resistance.　Moreover,　several　quinazoline　hybrids,　which　are　exemplified　by　tucatinib　and　lapatinib,　have　already　been　applied　in　clinics　for　the　treatment　of　breast　cancer,　revealing　that　quinazoline　hybrids　are　valuable　entities　for　the　exploitation　of　novel　antibreast　cancer　chemotherapeutics.　This　review　outlines　the　current　status　of　quinazoline　hybrids　with　antibreast　cancer　potential,　covering　articles　published　from　2020　onwards.　The　structure-activity　relationships　(SARs)　and　mechanisms　of　action　are　also　discussed　to　provide　a　potential　avenue　for　developing　more　effective　antibreast　cancer　candidates.